---
title: A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
date: '2024-06-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38847460/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240608181754&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Survodutide was superior to placebo with respect to improvement
  in MASH without worsening of fibrosis, warranting further investigation in phase
  3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number,
  NCT04771273; EudraCT number, ...'
disable_comments: true
---
CONCLUSIONS: Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis, warranting further investigation in phase 3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number, NCT04771273; EudraCT number, ...